CB 7646Alternative Names: Dimelamol
Latest Information Update: 26 Nov 2007
At a glance
- Originator Nonindustrial source
- Class Antineoplastics
- Mechanism of Action Alkylating agents
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 15 Jul 1999 CB 7646 is available for licensing
- 18 Apr 1996 Preclinical development for Cancer in United Kingdom (Unknown route)